Stockscreener 앱 받기
345.73
1.00%
3.44
시간 외 거래:
351.00
5.27
+1.52%
전일 마감가:
$342.29
열려 있는:
$340.98
하루 거래량:
352.91K
Relative Volume:
1.02
시가총액:
$7.68B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-13.76
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
+14.42%
1개월 성능:
+20.25%
6개월 성능:
+3.91%
1년 성능:
+41.90%
1일 변동 폭
$339.31
$348.34
1주일 범위
$299.17
$350.00
52주 변동 폭
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
345.73 | 7.54B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Party Time: Brokers Just Made Major Increases To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Earnings Forecasts - uk.finance.yahoo.com
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Leading vs lagging indicators on Madrigal Pharmaceuticals Inc. performanceSwing Trade Watchlist with Entry Zones - Newser
What to do if you’re stuck in Madrigal Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysFree Consistent Income Focused Trade List - Newser
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
MDGL Analyst Rating Update: Canaccord Genuity Raises Price Targe - GuruFocus
Cautious Outlook on Madrigal Pharmaceuticals: Sell Rating Amid Competitive Pressures and Valuation Concerns - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53) - TipRanks
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial R - GuruFocus
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $212.8M, vs. FactSet Est of $162.0M - MarketScreener
Madrigal Pharmaceuticals Reports $212.8 Million in Second-Quarter 2025 Net Sales for Rezdiffra™, Secures New Patent and Licensing Agreement - Quiver Quantitative
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - biocentury.com
How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News
Is Madrigal Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with advanced market data - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockHigh-profit trading signals - Jammu Links News
How does Madrigal Pharmaceuticals Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketBuild wealth with reliable stock picks - Jammu Links News
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light - MSN
What are Madrigal Pharmaceuticals Inc. company’s key revenue driversInvest confidently with market-leading analysis - Jammu Links News
Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
What is the dividend policy of Madrigal Pharmaceuticals Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a good long term investmentUnlock your portfolio’s hidden potential - Jammu Links News
What makes Madrigal Pharmaceuticals Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
The week in pharma: action, reaction and insight – week to August 1 - The Pharma Letter
Published on: 2025-08-03 13:27:37 - Jammu Links News
When is Madrigal Pharmaceuticals Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):